<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02979912</url>
  </required_header>
  <id_info>
    <org_study_id>PEDUJCTC</org_study_id>
    <nct_id>NCT02979912</nct_id>
  </id_info>
  <brief_title>Autologous Platelet Lysate in Corneal Epithelial Defects</brief_title>
  <official_title>The Use of Autologous Platelet Lysate in Persistent Corneal Epithelial Defects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanan Jafar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Jordan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients diagnosed with persistent corneal epithelial ulcers will be treated with autologous&#xD;
      platelet lysate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous platelet lysate (PL) will be given to patients diagnosed with persistent corneal&#xD;
      epithelial ulcers (PED) who are unresponsive to conventional therapy to promote the healing&#xD;
      of PED. PL will be dispensed into sterile eye droppers, and these eye droppers will be stored&#xD;
      ideally at -20C and thaw once for use, then will be kept in the refrigerator at +4C, to be&#xD;
      taken in multiple doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2017</start_date>
  <completion_date type="Actual">January 30, 2019</completion_date>
  <primary_completion_date type="Actual">January 15, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]) as a result of the eye drops</measure>
    <time_frame>2 months</time_frame>
    <description>Evaluation of the safety and tolerability of PL in the treatment of PED by monitoring any adverse event resulting from the eye drops.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of the efficacy by clinical judgment</measure>
    <time_frame>6 months</time_frame>
    <description>Efficacy of the given eye drops will be clinically evaluated by measuring the degree of healing of the epithelial defect</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Persistent Corneal Epithelial Defect</condition>
  <arm_group>
    <arm_group_label>Platelet Lysate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Autologous platelet lysate dispensed into eye droppers to be applied four times a day for a total of four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Platelet Lysate</intervention_name>
    <description>Eye drops of Platelet Lysate</description>
    <arm_group_label>Platelet Lysate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Cognitive ability to understand and sign the consent form.&#xD;
&#xD;
          2. Corneal ulcers that did not re-epithelialise after 1 week of conventional treatment&#xD;
             (therapeutic contact lenses, topical artificial tears, eye packs and antibiotic&#xD;
             eye-drops).&#xD;
&#xD;
          3. Clinical indications: corneal ulcer due to caustic substances, corneal epitheliopathy,&#xD;
             corneal lesions following cataract surgery, recurrent ulcerative keratitis, corneal&#xD;
             lesions due to a foreign body.&#xD;
&#xD;
          4. Good compliance with the study regimen and availability for the duration of the entire&#xD;
             study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Corneal ulcers which developed tissue scars.&#xD;
&#xD;
          2. Pregnant or lactating women.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>78 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abdallah Awidi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cell Therapy Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cell Therapy Center</name>
      <address>
        <city>Amman</city>
        <zip>11942</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Jordan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>November 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2016</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Jordan</investigator_affiliation>
    <investigator_full_name>Hanan Jafar</investigator_full_name>
    <investigator_title>Researcher</investigator_title>
  </responsible_party>
  <keyword>Persistent corneal epithelial defect</keyword>
  <keyword>Platelet Lysate</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

